Table.
Demographic and Clinical Findings of Study Population
| Case No. | Sex/Age, y | DM Type | Duration of DM, y | Glycated Hb, % of Total Hb | HTN | HLD | KD | Study Eye | BCVA | DR Stage | Laser Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/early 50s | 2 | 12 | 12.3 | Yes | Yes | No | Right | 20/25 | PDR | Macular and PRP |
| 2 | F/mid-30s | 2 | 16 | 8.1 | Yes | No | No | Right (control) | 20/25 | Severe NPDR | None |
| Left | 20/20 | Severe NPDR | None | ||||||||
| 3 | M/late 50s | 2 | 6 | NA | Yes | No | No | Right | 20/30 | PDR | PRP |
| Left (control) | 20/30 | PDR | PRP | ||||||||
| 4 | F/late 50s | 2 | 20 | 9.2 | Yes | Yes | No | Left | 20/30 | PDR | Macular and PRP |
| 5 | M/early 40s | 2 | 15 | 5.9 | Yes | No | Yes | Right | 20/125 | PDR | PRP |
| 6 | M/early 50s | 2 | 12 | NA | Yes | No | No | Left | 20/50 | PDR | PRP |
| 7a | M/late 30s | 1 | 25 | 6.4 | Yes | No | No | Left | 20/30 | PDR | PRP |
| 8 | M/mid-50s | 2 | 10 | 8.4 | Yes | No | Yes | Right | 20/20 | PDR | PRP |
| Left (control) | 20/25 | PDR | PRP | ||||||||
| 9 | M/early 40s | 2 | 0.25 | NA | Yes | Yes | No | Right (control) | 20/20 | Moderate NPDR | None |
| Left | 20/30 | Moderate NPDR | None |
Abbreviations: BCVA, best-corrected visual acuity; DM, diabetes mellitus; DR, diabetic retinopathy; Hb, hemoglobin; HLD, hyperlipidemia; HTN, hypertension; KD, kidney disease; NA, not available; NPDR, nonproliferative DR; PDR, proliferative DR; PRP, panretinal photocoagulation.
SI conversion factor: To convert glycated Hb to proportion of total Hb, multiply by 0.01.
a
The patient had undergone pancreas and kidney transplantation 4 years prior to presentation.